Conference Coverage

Anticoagulation not routinely needed after TAVR: ADAPT-TAVR

Publish date: April 4, 2022

 

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Death of pig heart transplant patient is more a beginning than an end
MDedge Cardiology
Congress opens investigation into FDA’s handling of a problematic heart device
MDedge Cardiology
Surgery groups push back on VARC-3 valve trial definitions
MDedge Cardiology
Hybrid ACC 2022 resurrects the live scientific session
MDedge Cardiology
POISE-3 backs wider use of tranexamic acid in noncardiac surgery 
MDedge Cardiology
FAME 3 subanalysis adds twist to negative primary results
MDedge Cardiology
VALOR-HCM: Novel drug may delay, avert invasive therapy in OHCM
MDedge Cardiology
New HF guidelines feature ‘quad’ therapy, tweaked terminology
MDedge Cardiology
FDA approves leadless, single-chamber pacemaker system
MDedge Cardiology
Early PCSK9 inhibition in AMI yields plaque regression
MDedge Cardiology